A detailed history of Swiss National Bank transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 179,000 shares of NTLA stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
179,000
Previous 180,300 0.72%
Holding current value
$1.85 Million
Previous $4.04 Million 8.85%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$19.72 - $27.36 $25,636 - $35,568
-1,300 Reduced 0.72%
179,000 $3.68 Million
Q2 2024

Aug 08, 2024

BUY
$20.02 - $27.22 $248,248 - $337,528
12,400 Added 7.39%
180,300 $4.04 Million
Q1 2024

May 07, 2024

BUY
$23.82 - $32.8 $52,404 - $72,160
2,200 Added 1.33%
167,900 $4.62 Million
Q4 2023

Feb 06, 2024

SELL
$23.16 - $32.34 $201,492 - $281,358
-8,700 Reduced 4.99%
165,700 $5.05 Million
Q3 2023

Nov 08, 2023

BUY
$31.62 - $45.78 $60,078 - $86,982
1,900 Added 1.1%
174,400 $5.51 Million
Q2 2023

Aug 09, 2023

BUY
$34.58 - $46.03 $681,226 - $906,791
19,700 Added 12.89%
172,500 $7.03 Million
Q1 2023

May 10, 2023

SELL
$33.3 - $44.82 $412,919 - $555,768
-12,400 Reduced 7.51%
152,800 $5.69 Million
Q4 2022

Feb 08, 2023

BUY
$33.21 - $62.69 $109,593 - $206,877
3,300 Added 2.04%
165,200 $5.76 Million
Q3 2022

Nov 09, 2022

BUY
$53.92 - $71.7 $221,072 - $293,970
4,100 Added 2.6%
161,900 $9.06 Million
Q2 2022

Aug 09, 2022

SELL
$38.49 - $76.21 $23,094 - $45,725
-600 Reduced 0.38%
157,800 $8.17 Million
Q1 2022

May 09, 2022

BUY
$58.27 - $118.99 $751,683 - $1.53 Million
12,900 Added 8.87%
158,400 $11.5 Million
Q4 2021

Feb 08, 2022

BUY
$100.76 - $138.36 $997,524 - $1.37 Million
9,900 Added 7.3%
145,500 $17.2 Million
Q3 2021

Nov 08, 2021

BUY
$132.37 - $176.78 $158,844 - $212,136
1,200 Added 0.89%
135,600 $18.2 Million
Q2 2021

Aug 06, 2021

BUY
$60.88 - $161.91 $1.61 Million - $4.27 Million
26,400 Added 24.44%
134,400 $21.8 Million
Q1 2021

May 07, 2021

BUY
$46.59 - $83.68 $83,862 - $150,624
1,800 Added 1.69%
108,000 $8.67 Million
Q4 2020

Feb 05, 2021

BUY
$18.83 - $63.53 $58,372 - $196,943
3,100 Added 3.01%
106,200 $5.78 Million
Q3 2020

Nov 09, 2020

BUY
$17.47 - $24.93 $26,205 - $37,395
1,500 Added 1.48%
103,100 $2.05 Million
Q2 2020

Aug 05, 2020

BUY
$11.14 - $22.87 $402,154 - $825,607
36,100 Added 55.11%
101,600 $2.14 Million
Q4 2019

Feb 06, 2020

BUY
$10.43 - $17.67 $57,365 - $97,185
5,500 Added 9.17%
65,500 $961,000
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $14,377 - $20,361
1,100 Added 1.87%
60,000 $801,000
Q2 2019

Aug 02, 2019

BUY
$13.88 - $18.41 $227,632 - $301,924
16,400 Added 38.59%
58,900 $964,000
Q2 2018

Aug 09, 2018

BUY
$20.02 - $30.79 $86,086 - $132,397
4,300 Added 11.26%
42,500 $1.16 Million
Q1 2018

May 04, 2018

SELL
$19.43 - $34.95 $29,145 - $52,425
-1,500 Reduced 3.78%
38,200 $806,000
Q4 2017

Feb 07, 2018

BUY
$17.39 - $31.12 $330,410 - $591,280
19,000 Added 91.79%
39,700 $763,000
Q3 2017

Nov 03, 2017

BUY
$15.16 - $25.75 $313,812 - $533,025
20,700
20,700 $514,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $784M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.